Genistein Suppression of Matrix Metalloproteinase 2 (MMP-2) and Vascular Endothelial Growth Factor (VEGF) Expression in Mesenchymal Stem Cell Like Cells Isolated from High and Low Grade Gliomas |
Yazdani, Yasaman
(Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences)
Rad, Mohammad Reza Sharifi (Department of Neurosurgery, School of Medicine, Shiraz University of Medical Sciences) Taghipour, Mousa (Department of Neurosurgery, School of Medicine, Shiraz University of Medical Sciences) Chenari, Nooshafarin (Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences) Ghaderi, Abbas (Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences) Razmkhah, Mahboobeh (Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences) |
1 | Su S-J, Yeh T-M, Chuang W-J, et al (2005). The novel targets for anti-angiogenesis of genistein on human cancer cells. Biochem Pharmacol, 69, 307-18. DOI |
2 | Weber GF, Bjerke MA, DeSimone DW (2011). Integrins and cadherins join forces to form adhesive networks. J Cell Sci, 124, 1183-93. DOI |
3 | Weinstein IB (2002). Addiction to oncogenes-the Achilles heal of cancer. Science, 297, 63-4. DOI |
4 | Yu X, Zhu J, Mi M, et al (2012). Anti-angiogenic genistein inhibits VEGF-induced endothelial cell activation by decreasing PTK activity and MAPK activation. Med Oncol, 29, 349-57. DOI |
5 |
Brooks PC, Stromblad S, Sanders LC, et al (1996). Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin |
6 | Abdullah JM, Mustafa Z, Ideris A (2014). Newcastle disease virus interaction in targeted therapy against proliferation and invasion pathways of glioblastoma multiforme. Biomed Res Int, 2014, 386470. |
7 | Bourboulia D,Stetler-Stevenson WG (2010). Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Sem Cancer Biol, 20, 161-8. DOI |
8 | Brewer GJ, LeRoux PD (2007). Human primary brain tumor cell growth inhibition in serum-free medium optimized for neuron survival. Brain Res, 1157,156-66. DOI |
9 | Gadgeel SM, Ali S, Philip PA, Wozniak A,Sarkar FH (2009). Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines. Cancer, 115, 2165-76. DOI |
10 | Forsyth P, Wong H, Laing T, et al (1999). Gelatinase-A (MMP- 2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer, 79,1828. DOI |
11 | Le DM, Besson A, Fogg DK, et al (2003). Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade. J Neurosci, 23, 4034-43. DOI |
12 | Gomes FG, Nedel F, Alves AM, Nor JE,Tarquinio SBC (2013). Tumor angiogenesis and lymphangiogenesis: tumor/ endothelial crosstalk and cellular/microenvironmental signaling mechanisms. Life Sci, 92,101-7. DOI |
13 |
Han L, Zhang H, Zhou W, Chen G, Guo K (2012). The effects of genistein on transforming growth factor- |
14 | Khaw AK, Yong JWY, Kalthur G,Hande MP (2012). Genistein induces growth arrest and suppresses telomerase activity in brain tumor cells. Genes Chromosomes Cancer, 51,961-74. DOI |
15 | Myoung H, Hong SP, Yun PY, Lee JH, Kim MJ (2003). Anti-cancer effect of genistein in oral squamous cell carcinoma with respect to angiogenesis and in vitro invasion. Cancer Sci, 94, 215-20. DOI |
16 | Li Y, Sarkar FH (2002). Down-regulation of invasion and angiogenesis-related genes identified by cDNA microarray analysis of PC3 prostate cancer cells treated with genistein. Cancer Lett, 186, 157-64. DOI |
17 | Maule F, Bresolin S, Rampazzo E, et al (2016). Annexin 2A sustains glioblastoma cell dissemination and proliferation. Oncotarget, 7, 54632. DOI |
18 | Munson J, Bonner M, Fried L, et al (2013). Identifying new small molecule anti-invasive compounds for glioma treatment. Cell Cycle, 12, 2200-9. DOI |
19 | Nakahata AM, Suzuki DE, Rodini CO, et al (2010). Human glioblastoma cells display mesenchymal stem cell features and form intracranial tumors in immunocompetent rats. World J Stem Cells, 5,103-11. |
20 | Nakamura Y, Yogosawa S, Izutani Y, et al (2009). A combination of indole-3-carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and progression of autophagy. Mol Cancer, 8,1. |
21 | Plaisier CL, O'Brien S, Bernard B, et al (2016). Causal mechanistic regulatory network for glioblastoma deciphered using systems genetics network analysis. Cell Systems, 3, 172-86. DOI |
22 | Puli S, Lai JC, Bhushan A (2006). Inhibition of matrix degrading enzymes and invasion in human glioblastoma (U87MG) cells by isoflavones. J Neurooncol, 79, 135-42. DOI |
23 | Shu XO, Zheng Y, Cai H, et al (2009). Soy food intake and breast cancer survival. JAMA, 302, 2437-43. DOI |
24 | Razmkhah M, Arabpour F, Taghipour M, et al (2013). Expression of chemokines and chemokine receptors in brain tumor tissue derived cells. Asian Pac J Cancer Prev, 15, 7201-5. |
25 | Russo M, Russo GL, Daglia M, et al (2016). Understanding genistein in cancer: The “good” and the “bad” effects: A review. Food Chem, 196, 589-600. DOI |
26 | Shao Z-M, Wu J, Shen Z-Z, Barsky SH (1998). Genistein exerts multiple suppressive effects on human breast carcinoma cells. Cancer Res, 58,4851-7. |
27 | Nakamura H, Wang Y, Kurita T, et al (2011). Genistein increases epidermal growth factor receptor signaling and promotes tumor progression in advanced human prostate cancer. PloS One, 6, e20034. DOI |
28 | Spagnuolo C, Russo GL, Orhan IE, et al (2015). Genistein and cancer: current status, challenges, and future directions. Advances in Nutrition. ADV NUTR, 6, 408-19. DOI |
29 | Stupp R, Mason WP, Van Den Bent MJ, et al (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 352, 987-96. DOI |
![]() |